Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Whole-exome sequencing identifies R1279X of MYH6 gene to be associated with congenital heart disease

BMC Cardiovascular Disorders201818:137

https://doi.org/10.1186/s12872-018-0867-4

©  The Author(s). 2018

  • Received: 19 February 2018
  • Accepted: 20 June 2018
  • Published:
Open Peer Review reports

Abstract

Background

Myosin VI, encoded by MYH6, is expressed dominantly in human cardiac atria and plays consequential roles in cardiac muscle contraction and comprising the cardiac muscle thick filament. It has been reported that the mutations in the MYH6 gene associated with sinus venosus atrial septal defect (ASD type III), hypertrophic (HCM) and dilated (DCM) cardiomyopathies.

Methods

Two patients in an Iranian family have been identified who affected to Congenital Heart Disease (CHD). The male patient, besides CHD, shows that the thyroglossal sinus, refractive errors of the eye and mitral stenosis. The first symptoms emerged at the birth and diagnosis based on clinical features was made at about 5 years. The family had a history of ASD. For recognizing mutated gene (s), whole exome sequencing (WES) was performed for the male patient and variants were analyzed by autosomal dominant inheritance mode.

Results

Eventually, by several filtering processes, a mutation in MYH6 gene (NM_002471.3), c.3835C > T; R1279X, was identified as the most likely disease-susceptibility variant and then confirmed by Sanger sequencing in the family. The mutation frequency was checked out in the local databases. This mutation results in the elimination of the 660 amino acids in the C-terminal of Myosin VI protein, including the vital parts of the coiled-coil structure of the tail domain.

Conclusions

Our study represents the first case of Sinus venosus defect caused directly by MYH6 stop codon mutation. Our data indicate that by increase haploinsufficiency of myosin VI, c.3835C > T mutation with reduced penetrance could be associated with CHD.

Keywords

  • MYH6
  • Congenital heart disease
  • ASD type III
  • Nonsense mutation
  • WES

Background

Congenital Heart Defects (CHDs) are one of the major causes of death due to congenital malformations and show some of the more preponderant malformations among live births. It has been revealed that both familial and sporadic forms of CHDs result from mutations in several genes based on human cases and animal models [1, 2]. Based on targeted deletions studies in mice, it has been suggested that there are more than five hundred genes involved in heart disorders (Mouse Genome Informatics (http://www.informatics.jax.org)) [3]. CHDs treat greatly as a complex trait and to date, the number of familial cases has distinguished by the Mendelian segregation of single-gene mutations are so few [4].

Both inherited and non-inherited factors account for congenital heart disease (CHD). The incidence of CHD approximately is 0.4–0.6% live births and real prevalence is about 4% [5, 6]. Our knowledge about CHD’s causes and mechanisms remains restricted in spite of the advances in diagnosis and interventions. With development of whole exome/genome sequencing more CHD causing genes possibly will be clarified which will increase our insight into the genetic causes of CHD.

Numerous epidemiological studies have suggested a genetic component of CHD etiology. Approximately, 25% of CHD cases occur as a complex trait with related defects in other organs as a sporadic malformative association, Mendelian syndrome or chromosomal abnormality [7]. The rest of cases occur as isolated defects and both sporadic and familial cases that showing Mendelian patterns of inheritance, have been reported [8, 9]. To date, several diseases associated with MYH6 mutations such as hypertrophic (HCM), dilated cardiomyopathy (DCM) and atrial septal defect (ASD) have been reported [10]. ASD is categorized as the second most common CHD and accounts for 10% of all cardiac malformations [11]. Around 80% of persistent small ASDs close spontaneously during infancy or childhood, but the large one could cause serious defects such as congestive heart failure, pulmonary vascular disease and etc. [12]. There are various types of ASD; ASD type III — sinus venosus atrial septal defect— is caused by mutations in MYH6 [13]. It has not been identified any correlation between the stop codon mutations of MYH6 and ASD type III but in the present study, we could detect this correlation.

In the present study, we checked out a clinically characterized family with a history of congenital heart disease. In this family, we observed an obvious autosomal-dominant inheritance with reduced penetrance (K = 50%). We identified a novel nonsense mutation in MYH6, NM_002471.3 c.3835C > T; R1279X, by WES of the patient in SH1190831 family and then this mutation was confirmed by Sanger sequencing.

Methods

Patients and clinical evaluations

The study protocol was approved by the local medical ethics committee of Tarbiat Modares University, Tehran, Iran. Written informed consents were obtained from all individuals. All of the patient’s clinical information and the medical histories were collected at the Department of Medical Genetics, DeNA Laboratory, Tehran, Iran.

We enrolled 5 members of this family in our study (two affected, two unaffected and one carrier) (Table 1). Subjects were adjusted by meticulous medical records including a complete physical examination, a 12-lead Echocardiogram (ECG), Ultrasonic cardiogram (UCG) and other relevant features such as PR, QRS interval, QT, QTc duration and QRS axis were measured. QRS axis was presumed as normal when its value was measured between − 30° and + 90° and was classified abnormal when out of this range. The normal range of ECG was performed based on the individual ages. For adults, a PR interval above 210 ms and an increased above 100 ms of QRS interval were thought-out prolonged [14].
Table 1

Clinical and Electrocardiographic Features in Members of SH1190831 Family

Member

status

Age range(year)

Symptoms

Clinical ECG diagnosis

QRS axis

Heart Rate Beats/min

Electrocardiography

Mutation

RA (mm)

RV (mm)

LVEF (%)

III.1a,b

P

7-11

ASD type III, Thyroglossal Sinus, Mitral Stenosis, Refractive Errors Of The Eye

RBBB

− 58°

75

29

34

63

WT/p.R1279X

II.2

P

57–61

sinus venosus atrial septal defect (ASD type III)

RBBB

−65°

88

35

33

59

WT/p.R1279X

II.3

H

36–40

Asymptomatic

ND

+ 42°

93

26

32

67

WT/WT

II.4

H

43–47

Asymptomatic

ND

+ 43°

85

31

30

64

WT/p.R1279X

II.5

H

40–44

Asymptomatic

ND

+ 42°

83

23

28

66

WT/WT

NA Not Detected, ASD Atrial Septal Defect, RBBB Right Bundle Branch Block, P Patient, H Healthy

aWhole exome sequence is applied to this individual

bIndex case

DNA extraction

Genomic DNA was isolated from peripheral blood of the family members by the ROCHE DNA Extraction Kit (Cat. No. 11814770001). DNA concentration was measured by Thermo Scientific™ Nanodrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA).

NGS study

Exome capturing and high throughput sequencing (HTS) was performed on the proband (III:1). The Nextera Rapid Capture Exome kit with 340,000 probes designed against the human genome was utilized to enrich the approximately 37 Mb (214,405 exons) of the Consensus Coding Sequences (CCS) from fragmented genomic DNA. Due to limitations of the method, not all exons were fully covered and all of the pathogenic variants cannot be totally excluded. An overall coverage of 98.19% was achieved, with 2188 missing base pairs (a coding region including ±2 bp). At the next step, an end to end in-house bioinformatics pipelines including base calling, primary filtering of low-quality reads and probable artifacts, and annotation of variants were applied.

The reads were aligned to the NCBI human reference genome (gh19/NCBI37.1) with SNP & Variation Suite version 8.0 (SVS v8.0) and DNASTAR Lasergene12 (DNASTAR Inc., Madison, Wisconsin USA). Small indel detection was used with the Unified Genotyper tool from GATK tools in Galaxy online database (http://www.usegalaxy.org). The missense, nonsense, silent, and indel mutations rates were estimated by Galaxy online tool and finally were confirmed by Ivariantguide® (https://www.advaitabio.com).

Because of the Autosomal dominant nature of the mutation, for the first step, we assumed that the variant (s) should be transferred in heterozygote manner, so we excluded the homozygote variants and then several filtering steps were applied to prioritize all variants: 1) Variants in dbSNP132 (https://www.ncbi.nlm.nih.gov/projects/SNP) and 1000 Genomes Project (http://www.1000genomes.org) with allele frequencies more than 1% were excluded. 2) The rest of variants underwent further exclusion in Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS) and Exome Aggregation Consortium (ExAC) database. 3) The intragenic, intronic, UTRs regions and synonymous variants were excluded from later analysis. 4) The SIFT (http://sift.jcvi.org/), Provean (http://provean.jcvi.org) and Mutation Taster (http://www.mutationtaster.org) were used to predict variants pathogenicity (Table 2).
Table 2

Several online databases that used to confirm the pathogenicity of the R1279X mutation in MYH6 gene

Mutation Taster

EXAC

SIFT

1000 Genome

Iranome

PROVEAN

Damaging

Not reported

Damaging

Not reported

Not reported

Damaging

All suspected pathogenic variants were checked out in HGMD (http://www.hgmd.cf.ac.uk) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar). Finally, based on family pedigree, autosomal dominant inheritance pattern and clinical information were used to evaluate identified variants. Based on the clinical information, specific attention has been paid to the 42 genes known Congenital Heart Diseases. ConSurf (http://www.consurf.tau.ac.il) database was applied to provide evolutionary conservation profile for Myosin VI protein and showing the staple role of the mutation (Fig. 2c). As well as, frequency of the mutation was checked out based on the local database (http://www.iranome.ir); all information related to the In-silico prediction such as conservation, allele frequency, and damaging prediction were depicted in Table 2.

Mutation validation and co-segregation analysis

Sanger sequencing in forward and reverse directions was performed to validate the candidate variants found in WES and then segregation analyses were performed in the family. The primers were designed by Primer3.0 (http://bioinfo.ut.ee/primer3-0.4.0) web-based server (Table 3). We checked out the lack of SNPs in the genomic region corresponding to the 3′ ends of primers by looking through the dbSNP database. The primers specificity was checked by the in-silico-PCR tool in UCSC genome browser and Primer blast of NCBI genome browser and finally, the PCR was utilized in standard conditions and then the polymerase chain reaction (PCR) products were sequenced by ABI 730XL, using the conventional capillary system, and then the Sequences were analyzed by Genome Compiler online tool (http://www.genomecompiler.com/) to identify the alternations.
Table 3

Sequences of the primers used to confirm the mutation by Sanger sequencing

Patient ID

Gene

Variant

Primers

SH1190831

MYH6

c.3835C > T

(p.R1279X)

F 5′-CACACTCACCCTTCCTGTCT-3′

R 5′-CTGAAATGAGGGGCTTGTGG-3′

Results

Clinical features

We identified two patients — the female and the male patients— in an Iranian family. The female patient had sinus venosus atrial septal defect, although the male patient manifested other symptoms, as well as ASD type III, such as thyroglossal sinus to refractive errors of the eye and mitral stenosis. The proband (III.1), a male was between the age range of 12–16, affected with ASD and Thyroglossal sinus. Both parents were assessed for the relevant clinical features but we could not detect any relevant symptoms. Physical examination demonstrated ASD in the patients (Table 1). The family history examination clarified that the patient II2 has the same condition. The II.4 sample, in spite of carrying the mutation, indicated no obvious phenotype implying the reduced penetrance in this condition. All family members were recruited for further physical examination and all gathered records have been reported in Table 1.

Genetic analysis

It is postulated that the pedigree may represent an autosomal dominant inheritance with reduced penetrance. To elucidate the underlying genetic cause (s), genomic DNA was obtained from the patient and analyzed by whole exome sequencing (WES). R1279X mutation was confirmed by Sanger sequencing (Fig. 1b).
Fig. 1
Fig. 1

Pedigree, chromatograms and filtering procedures in the SH1190831 family. a Pedigree of SH1190831 family is comprised of three generations. The squares and circles indicate males and females, respectively. The arrow appoints the proband of the family. The mutation, c.3835C > T in MYH6, has been demonstrated that segregated in this family. b Sequence chromatogram showing heterozygote state of the nucleotide sequence of MYH6 in c.3835C > T. c Schematic representation of filtering strategies that applied in this research. The filtering process was applied according several strategies which are demonstrated in the schematic representation. For more investigation, we reevaluated the filtering steps by regard to this fact that the disease could be engendered by autosomal recessive; however, we could not detect any relevant variants according to this supposition

The detected SNVs and deletion/insertions were analyzed by several filtering methods. 66,109 variants were found in the exome of the proband after alignment and SNV calling. After several exclusion processes by using of dbSNP132, 1000 Genomes Project, Exome Sequencing Project (ESP), and ExAc databases, thirteen variants were identified and then prioritized by patients’ phenotype. Eventually, with the patient’s phenotypes, only one relevant variant was identified that shared by two affected and one carrier family members (II2, III1, II4) but not observed in other healthy parent or normal control (II5).

In the same statement, of the 1187 variants, 13 were ranked using three database tools (Provean, Mutation Taster, Sift) and finally, among the thirteen variants, a unique variant was opted as a pathogenic mutation of this unique family based on patient’s phenotype by utilizing CentoMD (https://www.centogene.com) and ClinVar. (https://www.ncbi.nlm.nih.gov/clinvar/) (Fig. 1c).

Samples from the available members of the SH1190831 family were subjected to Sanger sequencing to confirm the candidate variant of MYH6 gene.

To find the main cause of CHD in the proband by known genetic mutation (s), based on proband phenotype, we especially focused on the 42 genes that have critical roles in CHD etiology and revised our strategies with a filter of pertinent variants in these genes (Additional file 1: Table S1). The single patient analysis concentrated on the possibility of a known causative gene that underlies CHD.

Discussion

Atrial septal defect (ASD), a persistent interatrial communication, is one of the common congenital abnormalities occurring in various forms consists of ostium secundum (ASD type II, ~ 75% of cases), ostium primum (ASD type I, 15–20%), sinus venosus (ASD type III, 5–10%), and rarely, coronary sinus defects [15]. ASDs, based on the defected gene, have been classified into several groups. The mutations in various genes have been associated with atrial septal defects, for instance, mutations in NKX2–5, GATA4, TBX5, and MYH6 [16].

It has been identified that there are at least 35 classes of molecular motors into the myosin superfamily that move along actin filaments [17]. Several studies have described various functions for Myosin VI such as membrane trafficking, endocytosis, organizing and stabilizing the actin cytoskeleton and playing a material role in inner-ear hair cells [18–20]. Myosin VI is the merely class of myosin that known to move toward the minus-end of actin filaments. Intuitively, dimerization of the myosin can expand its movement along actin filament but it must be noticed that the Myosin VI does not contain a well-defined coiled-coil dimerization domain, suggesting that myosin-VI does not form a constitutive dimer on its own. The MYH6 gene encodes Myosin heavy chain, α isoform (MHC-α) in human Myosin VI [21]. This protein has several important domains such as head domain, IQ domain, cargo-binding domain, tail domain and etc. (Fig. 2). The tail domain involves two distinct section: Coiled-coil domain and globular domain. It has been identified that the tail domain has a staple role in interacting with the target, especially uncoated vesicles [22].
Fig. 2
Fig. 2

Schematic structure of MYH6 and Myosin VI protein domains. a The MYH6 gene is located on chromosome 14q12 and composed of 39 exons. MYH6 codes a protein that comprised of 1928 amino acids. The myosin heavy chain-α (MHC- α) is a hexameric protein (shown by red arrows). The upper red arrow exhibits the position of the mutation, c.3835C > T found in this study. This mutation is located in exon 27 or tail domain region of myosin VI protein. b Myosin VI is composed of four various parts. The head domain (blue), Motor Head, binds to actin filaments and hydrolyze ATP; Dimerization is mediated by α-helical coiled-coil domain (Yellow); Tail domain plays a critical role in binding to target proteins. The identified mutation, R1279X, predicted influence on Myosin VI ability to bind a cargo, and it is responsible to emerge a wide phenotype range in these patients. c The amino acid sequence MYH6 (p.R1279) colored based on conservation scores by ConSurf database

NGS and particularly whole exome sequencing techniques have been developed into a robust and cost-effective tool to identify the new variants or genes for rare Mendelian unknown disorders [23–25]. This technique has been used in genetic diagnostics helping to increase the clinical and mutational spectrum of known and unknown diseases [26, 27]. But sometimes it is so difficult to distinguish between pathogenic and benign mutations [28, 29]. Several filtering strategies have been developed to exclude variants that are implausible to cause disease.

In this study, we utilized the WES technique to identify a nonsense mutation at nucleotide 3835 of MYH6 gene. This mutation is located at the extremely conserved region in MYH6 gene in Primates, Myosin heavy chain-α isoform (MHC-α), and it is presumed to result in a truncated protein that is associated with Cardiomyopathy and ASD type 3 (OMIM: 614089, 613,251). Previously, it has been reported that the mutations in MYH6 are associated with late-onset hypertrophic cardiomyopathy, atrial septal defects and sick sinus syndrome [14, 30]. There are numerous reports on the association of MYH6 mutations and CHD [31].

In the present study, we identified a nonsense variant, c.3835C > T, R1279X, by whole exome sequencing in the coiled-coil region or tail domain of MYH6 gene. This region mediates interaction with cargo molecules or other myosin subunits. After several staple filtering and annotation processes, to predict whether the variant was deleterious or not, we utilized several databases such as SIFT, Mutation Taster, and Provean. We also analyzed intronic, synonymous, nonsense, missense and frameshift indel changes to predict whether those changes could affect splicing process by influencing on donor or acceptor splice sites, with mutation taster and Neutral Network Splice (NNSplice version 0.9).

It has been illustrated that the reduced penetrance could take the Centre stage in increasing prevalence atrial septal defects in familial form. According to the Sanger sequencing results, the mother of the patient, II.4, is a carrier for R1279X mutation. It could be justified by reduced penetrance. This phenomenon can make genetic counseling more challenging because of the difficult interpretation of a person’s family medical history and prediction the risk of passing a genetic condition to offspring.

R1279X mutation could increase the truncated proteins in the cell and, as a result, cell should prevent this process by Nonsense-mediated decay response (NMD response) which is increasingly appreciated as one of the central mechanisms of RNA surveillance, with a big deal role not only in physiological control of gene expression but also in modulating defects and acquired genetic diseases. NMD could confront the cells with reduced amounts of the protein which has known haploinsufficiency (i.e., reduced amounts of protein due to a mutant or null allele) [32]. In nutshell, NMD must be considered when the functional effect of the premature termination codon (PTC). It has been identified that the haploinsufficiency has a staple role in the pathogenesis of cardiovascular diseases [33, 34]. Based on the nonsense mutation influence on proteins, we propose haploinsufficiency as a predicted mechanism of pathogenesis of c.3835C > T, R1279X mutation in the patients, but more studies need to uncover the exact mechanism of CHD pathogenicity.

Our result indicates that this nonsense mutation (R1279X) in MYH6 might be the genetic cause of congenital heart disease. Our study confirms that the MYH6 gene has an important role in heart functions but we recommend the applying animal modeling to scrutinize the distinctive role of this mutation.

Conclusions

For the first time, we identified a nonsense mutation, c.3835C > T, R1279X, in MYH6 gene as a possible cause of CHD in an Iranian family. This finding will increase our knowledge about the aetiology of this rare condition by effective clarification of the causative gene mutations and will enhance the mutational spectrum of CHD and should consider in the diagnosis of these diseases.

Abbreviations

ASD: 

Atrial septal defect

CCS: 

Consensus Coding Sequences

CHD: 

Congenital Heart Disease

DCM: 

dilated cardiomyopathies

ECG: 

12-lead Echocardiogram

ESP: 

Exome Sequencing Project

HCM: 

hypertrophic cardiomyopathies

HTS: 

high throughput sequencing

UCG: 

Ultrasonic cardiogram

WES: 

Whole-Exome sequencing

Declarations

Acknowledgements

We thank the family for their participation in this study. We are especially grateful to the staffs of DeNA laboratory for helping us in this research and additionally, we appreciate supports from Dr. Elika Esmaeilzadeh and Dr. Farveh Ehya, Tarbiat Modares University, Tehran, Iran. This research received no specific grant from any funding agency, commercial or not for profit sectors.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due the principle of confidentiality of funding but are available from the corresponding author on reasonable request.

Authors’ contributions

Conceived and designed the experiments: MG Conducted the experiments: MG, ER Analysed the data: ER Contributed reagents/materials/analysis tools: MG, ER Wrote the paper: ER, MG. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the local medical ethics committee of Tarbiat Modares University, Tehran, Iran. Informed written consents were obtained from all individuals. All of the patient’s clinical information and the medical histories were collected at the Department of Medical Genetics, DeNA Laboratory, Tehran, Iran. The parental consent was obtained for the patient who was under 16.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
(2)
Department of Medical Genetics, DeNA laboratory, Tehran, Iran

References

  1. Calcagni G, Digilio MC, Sarkozy A, Dallapiccola B, Marino B. Familial recurrence of congenital heart disease: an overview and review of the literature. Eur J Pediatr. 2007;166(2):111–6.View ArticlePubMedGoogle Scholar
  2. Fahed AC, Gelb BD, Seidman J, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112(4):707–20.View ArticlePubMedGoogle Scholar
  3. Ghosh TK, Granados-Riveron JT, Buxton S, Setchfield K, Loughna S, Brook JD. Studies of genes involved in congenital heart disease. Journal of Cardiovascular Development and Disease. 2014;1(1):134–45.View ArticleGoogle Scholar
  4. El Malti R, Liu H, Doray B, Thauvin C, Maltret A, Dauphin C, Gonçalves-Rocha M, Teboul M, Blanchet P, Roume J. A systematic variant screening in familial cases of congenital heart defects demonstrates the usefulness of molecular genetics in this field. Eur J Hum Genet. 2016;24(2):228.View ArticlePubMedGoogle Scholar
  5. Pierpont ME, Basson CT, Benson DW, Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart defects: current knowledge. Circulation. 2007;115(23):3015–38.View ArticlePubMedGoogle Scholar
  6. Wren C, Irving CA, Griffiths JA, O’Sullivan JJ, Chaudhari MP, Haynes SR, Smith JH, Hamilton JL, Hasan A. Mortality in infants with cardiovascular malformations. Eur J Pediatr. 2012;171(2):281–7.View ArticlePubMedGoogle Scholar
  7. Gill HK, Splitt M, Sharland GK, Simpson JM. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol. 2003;42(5):923–9.View ArticlePubMedGoogle Scholar
  8. Robert E. In: Ferencz C, Rubin JD, Loffredo C, Magee CA, editors. Epidemiology of congenital heart disease: the Baltimore-Washington infant study, 1981–1989 (perspectives in pediatric cardiology series, volume 4), vol. 376. Armonk, New York: Futura Publishing Company, Inc; 1993. $75. In.: Pergamon; 1994.Google Scholar
  9. Ferencz C, Neill CA, Boughman JA, Rubin JD, Brenner JI, Perry LW. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J Pediatr. 1989;114(1):79–86.View ArticlePubMedGoogle Scholar
  10. Carniel E, Taylor MR, Sinagra G, Di Lenarda A, Ku L, Fain PR, Boucek MM, Cavanaugh J, Miocic S, Slavov D. α-Myosin heavy chain. Circulation. 2005;112(1):54–9.View ArticlePubMedGoogle Scholar
  11. Qm Z, Xj M, Jia B, Gy H. Prevalence of congenital heart disease at live birth: an accurate assessment by echocardiographic screening. Acta Paediatr. 2013;102(4):397–402.View ArticleGoogle Scholar
  12. Nyboe C, Olsen MS, Nielsen-Kudsk J, Hjortdal V. Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. Heart. 2015;0:1-6.heartjnl-2014-306552.Google Scholar
  13. Ouyang P, Saarel E, Bai Y, Luo C, Lv Q, Xu Y, Wang F, Fan C, Younoszai A, Chen Q. A de novo mutation in NKX2. 5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death. Clin Chim Acta. 2011;412(1):170–5.View ArticlePubMedGoogle Scholar
  14. Posch MG, Waldmuller S, Müller M, Scheffold T, Fournier D, Andrade-Navarro MA, De Geeter B, Guillaumont S, Dauphin C, Yousseff D. Cardiac alpha-myosin (MYH6) is the predominant sarcomeric disease gene for familial atrial septal defects. PLoS One. 2011;6(12):e28872.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Martin SS, Shapiro EP, Mukherjee M. Atrial septal defects – clinical manifestations, Echo assessment, and intervention. Clinical Medicine Insights Cardiology. 2014;8(Suppl 1):93–8.PubMedGoogle Scholar
  16. Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet. 2014;383(9932):1921–32.View ArticlePubMedGoogle Scholar
  17. Odronitz F, Kollmar M. Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species. Genome Biol. 2007;8(9):R196.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Frank DJ, Noguchi T, Miller KG. Myosin VI: a structural role in actin organization important for protein and organelle localization and trafficking. Curr Opin Cell Biol. 2004;16(2):189–94.View ArticlePubMedGoogle Scholar
  19. Mermall V, McNally JG, Miller KG. Transport of cytoplasmic particles catalysed by an unconventional myosin in living Drosophila embryos. Nature. 1994;369(6481):560–2.View ArticlePubMedGoogle Scholar
  20. Buss F, Arden SD, Lindsay M, Luzio JP, Kendrick-Jones J. Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. EMBO J. 2001;20(14):3676–84.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Tanigawa G, Jarcho JA, Kass S, Solomon SD, Vosberg H-P, Seidman J, Seidman CE. A molecular basis for familial hypertrophic cardiomyopathy: an αβ cardiac myosin heavy chain hybrid gene. Cell. 1990;62(5):991–8.View ArticlePubMedGoogle Scholar
  22. Hasson T. Myosin VI: two distinct roles in endocytosis. J Cell Sci. 2003;116(17):3453–61.View ArticlePubMedGoogle Scholar
  23. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010;42(1):30–5.View ArticlePubMedGoogle Scholar
  24. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med. 2013;369(16):1502–11.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Razmara EBF, Esmaeilzadeh-Gharehdaghi E, Almadani N, Garshasbi M. The first case of NSHL by direct impression on EYA1 gene and identification of one novel mutation in MYO7A in the Iranian families. Iran J Basic Med Sci. 2018;21:6–9.Google Scholar
  26. Churko JM, Mantalas GL, Snyder MP, Wu JC. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circ Res. 2013;112(12):1613–23.View ArticlePubMedGoogle Scholar
  27. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485(7397):237–41.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11):745–55.View ArticlePubMedGoogle Scholar
  29. Landstrom A, Ackerman MJ. The Achilles’ heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise. Clinical Pharmacology & Therapeutics. 2011;90(4):496–9.View ArticleGoogle Scholar
  30. Ching Y-H, Ghosh TK, Cross SJ, Packham EA, Honeyman L, Loughna S, Robinson TE, Dearlove AM, Ribas G, Bonser AJ. Mutation in myosin heavy chain 6 causes atrial septal defect. Nat Genet. 2005;37(4):423–8.View ArticlePubMedGoogle Scholar
  31. Weismann CG, Gelb BD. The genetics of congenital heart disease: a review of recent developments. Curr Opin Cardiol. 2007;22(3):200–6.View ArticlePubMedGoogle Scholar
  32. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet. 2004;36(8):801.View ArticlePubMedGoogle Scholar
  33. Marston S, Copeland ON, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009;105(3):219–22.View ArticlePubMedGoogle Scholar
  34. Cattin M-E, Bertrand AT, Schlossarek S, Le Bihan M-C, Skov Jensen S, Neuber C, Crocini C, Maron S, Lainé J, Mougenot N. Heterozygous Lmna delK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet. 2013;22(15):3152–64.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us